Indegene Limited Reports 21% Revenue Rise and Proposes ₹2.25 Dividend
Verified article - details checked for accuracy.
Data Extracted via Frism DocuLens
Indegene Limited posted FY2026 revenue of ₹35.825 bn, a 21% YoY rise, and generated strong cash flow despite modest profit growth.
- Revenue hit ₹35.825 bn (up 21% YoY) with Q4 sales of ₹10.142 bn; profit after tax rose only 1% to ₹4.011 bn, and basic EPS fell to ₹16.72 due to higher share count and goodwill amortisation.
- Operating cash flow surged 47% to ₹6.508 bn, cash balances grew to ₹3.008 bn, enabling a proposed final dividend of ₹2.25 per share (≈ ₹542 mn cash outflow).
- Acquisitions added ₹11.343 bn of goodwill (up from ₹3.565 bn) – BioPharm Parent Holding Inc. (₹8,821 mn), Warn & Co Limited (₹464 mn) and Cake Kommunikations Group (₹904 mn) – driving a net investing cash outflow of ₹5.124 bn.
- Segment re‑organisation now reports two units: Enterprise Commercial Solutions (₹24.605 bn, 70% of revenue) and Enterprise Medical Solutions (₹9.298 bn); management expects revenue growth above 15% YoY and pro‑forma FY2026‑27 revenue to exceed ₹38 bn.
Complete ArticleExclusive Frism Intelligence Report
Frism is a financial information and news discovery platform. We provide factual summaries and data correlations for educational and informational purposes only. Frism does not provide investment advice, buy/sell recommendations, or directional market outlooks. Users should consult a qualified financial advisor before making any investment decisions.
Proudly crafted in India 🇮🇳
Frism Computing (OPC) Private Limited
#74, 15TH CROSS, JP Nagar III Phase, Bangalore South, Bangalore 560078, Karnataka